Agenus Inc. is 10% Owner at MiNK Therapeutics, Inc. (INKT). They have made 7 open-market trades across 1 company since 2021, most recently 2023-10-16.
CIK 0001098972
7 open-market purchases totalling $17.9M since 2021, never a sale. Across 7 scored buys the stock is down 23.7% at ninety days, and 29.4 points behind the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| INKT | 21,772,863 | $218.2M |
Shares reported on the most recent Form 4, priced at the 2023-10-16 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 43% | 57% | 14% |
| Avg Move | +2.1% | -0.6% | -23.7% |
| Alpha | +2.5% | -1.9% | -29.4% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INKT | BUY | 2023-10-12 | 2023-10-16 | $1.10 | $25K | -17.3% | -7.3% | -20.9% |
| INKT | BUY | 2023-10-04 | 2023-10-06 | $1.09 | $16K | -8.3% | +0.8% | -6.7% |
| INKT | BUY | 2023-08-29 | 2023-08-31 | $1.52 | $45K | -15.0% | -30.6% | -30.6% |
| INKT | BUY | 2023-08-24 | 2023-08-28 | $1.54 | $543K | -13.6% | -20.1% | -36.4% |
| INKT | BUY | 2023-05-10 | 2023-05-12 | $1.47 | $67K | +13.2% | +19.8% | +5.5% |
| INKT | BUY | 2023-05-03 | 2023-05-05 | $1.05 | $399K | +1.7% | +2.8% | -2.8% |
| INKT | BUY | 2021-10-19 | 2021-10-20 | $12.00 | $16.8M | +54.4% | +30.2% | -74.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.